View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 5, 2022

AstraZeneca signs agreement to acquire TeneoTwo

Following the acquisition, AstraZeneca plans to advance the development of TNB-486 for B-cell hematologic malignancies.

AstraZeneca has signed an agreement for the acquisition of all outstanding equity of TeneoTwo as well as its CD19/CD3 T-cell engager, TNB-486, in a deal worth up to $1.27bn to bolster the haematological cancer pipeline.

As per the deal, AstraZeneca will make an upfront payment of $100m on the closing of the transaction.

Furthermore, equity holders of TeneoTwo are entitled to get up to $805m in research and development (R&D)-based milestone payments as well as up to $360m as commercial-related milestone payments from AstraZeneca.

A Phase I clinical-stage asset, TNB-486 is being analysed for relapsed and refractory B-cell non-Hodgkin lymphoma.

It attaches to CD19, an antigen expressed on B-cells, and CD3 receptor on T-cells to stimulate and recruit T-cells to CD19-expressing tumours, where they can induce an immune response.

Through the acquisition of TNB-486, AstraZeneca intends to expedite the development of this new therapy for B-cell hematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma. 

Building on Calquence’s (acalabrutinib) success, TNB-486 is expected to further expand the haematology pipeline of AstraZeneca that covers various therapeutic modalities and mechanisms for addressing a wide range of blood cancers.

AstraZeneca Haematology R&D senior vice-president Anas Younes said: “By redirecting the body’s natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy could potentially deepen clinical responses and improve patient outcomes. 

“We believe this innovative molecule, which was designed to optimise the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting.”

Subject to necessary conditions and approvals, the deal is anticipated to conclude in the third quarter of this year.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology